EXCLUSIVE: NanoViricides' Remdesivir-Encapsulated COVID-19 Therapy Shows Encouraging Preclinical Safety Profile

NanoViricides Inc NNVC has reported significant advantages gained by remdesivir encapsulation within its lead COVID-19 candidate, thus showing a potential pan-coronavirus cure.
Related Link: EXCLUSIVE: NanoViricides Beefs Up Its COVID-19 Pipeline With TheraCour Licensing Pact.
The Company is currently pursuing two COVID-19 drug candidates.
NV-CoV-2 is a nanoviricide drug candidate that does not encapsulate remdesivir.
NV-CoV-2-R is another candidate made up of NV-CoV-2 with remdesivir encapsulated in it. Remdesivir was developed by Gilead Sciences Inc GILD.
The animal study showed that almost double the remdesivir remained intact in plasma when given as the encapsulated NV-CoV-2-R form, compared to the standard remdesivir formulation in Sulfobutylether-β-cyclodextrin sodium salt (SBECD), during the first day of dosing.
Additionally, remdesivir accumulation was observed on repeated dosing of NV-CoV-2-R.
After the fifth dose and following the standard remdesivir dosing pattern, the circulating level of remdesivir in plasma was 75% greater in the NV-Cov-2-R group than in the remdesivir group.
The increased intact circulating level did not increase toxicity.
These data demonstrate that the pan-coronavirus nanopviricide drug candidate NV-CoV-2-R minimizes the loss of remdesivir to bodily metabolism.
Price Action: NNVC shares closed 5.72% lower at $3.79 on Monday.